Clinical trial

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

NCT06890923

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-03-04

PhasePHASE2

Study timeline

Study start (actual)2025-03-04Date precision: day

Registry last updated2025-06-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Active Secondary Progressive Multiple Sclerosisunresolved

Interventions

Foralumab TZLS-401 100 µgDRUG

Sponsors & collaborators

Tiziana Life Sciences LTDlead sponsor

Mapped research locations

BostonMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06890923 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.